KR970706825A - A therapeutic agent for diseases caused by infection of Helicobacter (REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER) - Google Patents

A therapeutic agent for diseases caused by infection of Helicobacter (REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER)

Info

Publication number
KR970706825A
KR970706825A KR1019970702879A KR19970702879A KR970706825A KR 970706825 A KR970706825 A KR 970706825A KR 1019970702879 A KR1019970702879 A KR 1019970702879A KR 19970702879 A KR19970702879 A KR 19970702879A KR 970706825 A KR970706825 A KR 970706825A
Authority
KR
South Korea
Prior art keywords
group
formula
carbon atoms
hydrogen atom
helicobacter
Prior art date
Application number
KR1019970702879A
Other languages
Korean (ko)
Other versions
KR100407849B1 (en
Inventor
가쓰지 야마시따
다께히꼬 야마네
신이찌 사까시따
가즈노리 호소에
겐지 후지이
Original Assignee
후루따 다께시
가네가후찌 가가꾸 고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후루따 다께시, 가네가후찌 가가꾸 고오교 가부시끼가이샤 filed Critical 후루따 다께시
Publication of KR970706825A publication Critical patent/KR970706825A/en
Application granted granted Critical
Publication of KR100407849B1 publication Critical patent/KR100407849B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

헬리코박터의 감염에 기인하는 소화기 질환의 치료제에 관한 것으로, 화학식(Ⅰ) 또는 (Ⅱ)로 나타내는 리파마이신 유도체 또는 그의 생리적으로 허용되는 염을 유효 성분으로서 함유하는 것을 특징으로 한다 :The present invention relates to a therapeutic agent for gastrointestinal diseases caused by infection with Helicobacter, and is characterized by containing, as an active ingredient, a rifamycin derivative represented by the formula (I) or (II) or a physiologically acceptable salt thereof:

Description

헬리코박터의 감염에 기인하는 질환의 치료제(REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER)A therapeutic agent for diseases caused by infection of Helicobacter (REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER)

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is a trivial issue, I did not include the contents of the text.

Claims (3)

화학식(Ⅰ) 또는 (Ⅱ)를 표시되는 리파 마이신 유도체 또는 그의 생리적으로 허용되는 염을 유효 성분으로 하는 헬리코박터의 감염에 기인하는 소화기 질환 치료제 :A therapeutic agent for gastrointestinal diseases caused by infection of Helicobacter with an effective ingredient of a rifamycin derivative represented by the formula (I) or (II) or a physiologically acceptable salt thereof: 〔상기 화학식(Ⅰ) 중, X1는 산소 원자 또는 유황 원자를 표시하며, R1은 아세틸기 또는 수소 원자를 표시하며, R2는 수산기 또는 수소 원자를 표시하고, R3은{여기에서, R4및 R5는 서로 동일하거나 상이하며, 1 내지 3의 탄소수를 갖는 알킬기 또는(m은 1 내지 3의 정수를 나타냄)로 나타내는 기를 나타낸다}로 표시되는 기 또는{R6및 R7은 서로 동일하거나 상이하고, 수소 원자 또는 1 내지 3의 탄소수를 갖는 알킬기를 표시하며, X2는 산소 원자, 유황원자 또는 NR8(R8은 수소 원자, 1 내지 6의 탄소수를 갖는 알킬기 또는 -(CH2)nX3(n은 1내지 4의 정수로 표시하고, X3는 탄소수 1 내지 3의 알콕시기, 비닐기, 에티닐기 또는로 표시되는 기를 나타낸다)로 표시되는 기를 나타낸다}로 표시되는 기를 나타낸다〕로 표시되는 기를 표시한다 :[Formula (Ⅰ) of, X 1 denotes an oxygen atom or a sulfur atom, R 1 represent a hydrogen atom or an acetyl group, R 2 represents a hydroxyl group or a hydrogen atom, R 3 is Wherein R 4 and R 5 are the same or different and each is an alkyl group having 1 to 3 carbon atoms or (m represents an integer of 1 to 3), or a group represented by R 6 and R 7 are the same or different and each represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; X 2 is an oxygen atom, a sulfur atom or NR 8 (R 8 is a hydrogen atom, An alkyl group having a carbon number or - (CH 2 ) n X 3 (n is an integer of 1 to 4, X 3 is an alkoxy group having 1 to 3 carbon atoms, a vinyl group, an ethynyl group, Represents a group represented by the formula: < RTI ID = 0.0 > 〔상기 화학식 (Ⅱ) 중, R9는 탄소수 1 내지 7 의 알킬기를 표시한다〕.[In the formula (II), R 9 represents an alkyl group having 1 to 7 carbon atoms]. 화학식(Ⅰ) 또는 (Ⅱ)로 표시되는 리파 마이신 유도체 또는 그의 생리적으로 허용되는 염의, 헬리코박터의 감염에 기인하는 소화기 질환 치료제의 제조를 위한 용도 :Use of a rifamycin derivative represented by the formula (I) or (II) or a physiologically acceptable salt thereof for the preparation of a therapeutic agent for digestive diseases caused by infection with Helicobacter: 〔상기 화학식(Ⅰ) 중, X1는 산소 원자 또는 유황 원자를 표시하며, R1은 아세틸기 또는 수소 원자를 표시하며, R2는 수산기 또는 수소 원자를 표시하고, R3은{여기에서, R4및 R5는 서로 동일하거나 상이하며, 1 내지 3의 탄소수를 갖는 알킬기 또는(m은 1 내지 3의 정수를 나타냄)로 나타내는 기를 나타낸다}로 표시되는 기 또는{R6및 R7은 서로 동일하거나 상이하고, 수소 원자 또는 1 내지 3의 탄소수를 갖는 알킬기를 표시하며, X2는 산소 원자, 유황 원자 또는 NR8(R8은 수소 원자, 1 내지 6의 탄소수를 갖는 알킬기 또는 -(CH2)nX3(n은 1내지 4의 정수로 표시하고, X3는 탄소수 1 내지 3의 알콕시기, 비닐기, 에티닐기 또는로 표시되는 기를 나타낸다)로 표시되는 기를 나타낸다}로 표시되는 기를 나타낸다〕로 표시되는 기를 표시한다 :[Formula (Ⅰ) of, X 1 denotes an oxygen atom or a sulfur atom, R 1 represent a hydrogen atom or an acetyl group, R 2 represents a hydroxyl group or a hydrogen atom, R 3 is Wherein R 4 and R 5 are the same or different and each is an alkyl group having 1 to 3 carbon atoms or (m represents an integer of 1 to 3), or a group represented by Wherein R 6 and R 7 are the same or different and each represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms, X 2 represents an oxygen atom, a sulfur atom or NR 8 (R 8 represents a hydrogen atom, - (CH 2 ) n X 3 (wherein n is an integer of 1 to 4, and X 3 is an alkoxy group having 1 to 3 carbon atoms, a vinyl group, an ethynyl group, Represents a group represented by the formula: < RTI ID = 0.0 > 〔상기 화학식 (Ⅱ) 중, R9는 탄소수 1 내지 7 의 알킬기를 표시한다〕.[In the formula (II), R 9 represents an alkyl group having 1 to 7 carbon atoms]. 화학식(Ⅰ) 또는 (Ⅱ)로 표시되는 리파 마이신 유도체 또는 그의 생리적으로 허용되는 염의, 헬리코박터의 감염에 기인하는 소화기 질환의 치료 방법 :A method for treating gastrointestinal diseases caused by infections of Helicobacter in a rifamycin derivative represented by the formula (I) or (II) or a physiologically acceptable salt thereof: 〔상기 화학식(Ⅰ) 중, X1는 산소 원자 또는 유황 원자를 표시하며, R1은 아세틸기 또는 수소 원자를 표시하며, R2는 수산기 또는 수소 원자를 표시하고, R3은{여기에서, R4및 R5는 서로 동일하거나 상이하며, 1 내지 3의 탄소수를 갖는 알킬기 또는(m은 1 내지 3의 정수를 나타냄)로 나타내는 기를 나타낸다}로 표시되는 기 또는{R6및 R7은 서로 동일하거나 상이하고, 수소 원자 또는 1 내지 3의 탄소수를 갖는 알킬기를 표시하며, X2는 산소 원자, 유황 원자 또는 NR8(R8은 수소 원자, 1 내지 6의 탄소수를 갖는 알킬기 또는 -(CH2)nX3(n은 1내지 4의 정수로 표시하고, X3는 탄소수 1 내지 3의 알콕시기, 비닐기, 에티닐기 또는로 표시되는 기를 나타낸다)로 표시되는 기를 나타낸다}로 표시되는 기를 나타낸다〕로 표시되는 기를 표시한다 :[Formula (Ⅰ) of, X 1 denotes an oxygen atom or a sulfur atom, R 1 represent a hydrogen atom or an acetyl group, R 2 represents a hydroxyl group or a hydrogen atom, R 3 is Wherein R 4 and R 5 are the same or different and each is an alkyl group having 1 to 3 carbon atoms or (m represents an integer of 1 to 3), or a group represented by Wherein R 6 and R 7 are the same or different and each represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms, X 2 represents an oxygen atom, a sulfur atom or NR 8 (R 8 represents a hydrogen atom, - (CH 2 ) n X 3 (wherein n is an integer of 1 to 4, and X 3 is an alkoxy group having 1 to 3 carbon atoms, a vinyl group, an ethynyl group, Represents a group represented by the formula: < RTI ID = 0.0 > 〔상기 화학식 (Ⅱ) 중, R9는 탄소수 1 내지 7 의 알킬기를 표시한다〕.[In the formula (II), R 9 represents an alkyl group having 1 to 7 carbon atoms]. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: It is disclosed by the contents of the first application.
KR1019970702879A 1995-09-01 1996-08-29 Therapeutic agent for diseases caused by infection of Helicobacter KR100407849B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP22531795 1995-09-01
JP22531895 1995-09-01
JP95-225317 1995-09-01
JP95-225318 1995-09-01

Publications (2)

Publication Number Publication Date
KR970706825A true KR970706825A (en) 1997-12-01
KR100407849B1 KR100407849B1 (en) 2004-05-07

Family

ID=26526564

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702879A KR100407849B1 (en) 1995-09-01 1996-08-29 Therapeutic agent for diseases caused by infection of Helicobacter

Country Status (7)

Country Link
EP (1) EP0787494B1 (en)
KR (1) KR100407849B1 (en)
CA (1) CA2204007A1 (en)
DE (1) DE69632677T2 (en)
ES (1) ES2218597T3 (en)
TW (1) TW385250B (en)
WO (1) WO1997009047A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
DE69829905T2 (en) * 1997-02-28 2006-03-09 Kaneka Corp. Remedies for Helicobacter disease
KR100572090B1 (en) * 1998-02-24 2006-04-17 액티브 바이오틱스 인코포레이티드 Antimicrobial compositions with synergistic effect, drugs and remedies for digestive diseases containing the same, process for the production thereof and preparations associated therewith
US6316433B1 (en) * 1998-12-18 2001-11-13 Kaneka Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US7342011B2 (en) * 2003-08-22 2008-03-11 Activbiotics, Inc. Rifamycin analogs and uses thereof
WO2005058231A2 (en) 2003-12-10 2005-06-30 Activbiotics, Inc. Rifamycin analogs and uses thereof
AU2004308399A1 (en) 2003-12-23 2005-07-14 Activbiotics, Inc. Rifamycin analogs and uses thereof
DK2270133T3 (en) 2008-04-22 2015-09-07 Corporación Alimentaria Peñasanta Capsa Method of obtaining a new strain of Bifidobacterium bidifum with effect against infection with Helicobacter pylori

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130099C (en) * 1963-10-11
IT1056272B (en) * 1975-06-13 1982-01-30 Archifar Ind Chim Trentino PRODUCTS DERIVED FROM AROMATIC AMINES
DE2626296C2 (en) * 1975-06-13 1986-11-27 Farmitalia Carlo Erba S.p.A., Mailand/Milano Rifamycin compound and process for its preparation
JPS59231092A (en) * 1983-06-11 1984-12-25 Kanebo Ltd Phenothiazine-type rifamycin and its pharmaceutical use
JPS63183587A (en) * 1985-02-05 1988-07-28 Kanegafuchi Chem Ind Co Ltd Benzoxazino-rifamycin derivative
CA1304363C (en) * 1988-11-01 1992-06-30 Takehiko Yamane 3'-hydroxybenzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same

Also Published As

Publication number Publication date
EP0787494B1 (en) 2004-06-09
DE69632677D1 (en) 2004-07-15
EP0787494A1 (en) 1997-08-06
TW385250B (en) 2000-03-21
DE69632677T2 (en) 2005-06-16
ES2218597T3 (en) 2004-11-16
CA2204007A1 (en) 1997-03-13
KR100407849B1 (en) 2004-05-07
EP0787494A4 (en) 2000-04-26
WO1997009047A1 (en) 1997-03-13

Similar Documents

Publication Publication Date Title
KR950031068A (en) Combined Treatment of Osteoporosis
IL205420A (en) Immunoregulatory compounds and derivatives, pharmaceutical compositions and use thereof in treating inflammatory conditions of the gastrointestinal tract
KR940007022A (en) Piperidine derivatives, their use in the preparation and treatment thereof
FR2762843B1 (en) NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
KR940701264A (en) Use of Macrolide Compounds for Ophthalmic Diseases
KR920003968A (en) Treatment of inflammatory bowel disease
KR970707108A (en) (DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS)
EP0992509A3 (en) Novel macrolide derivatives
KR970706825A (en) A therapeutic agent for diseases caused by infection of Helicobacter (REMEDY FOR DISEASES CAUSED BY INFECTION WITH HELICOBACTER)
RU2003134629A (en) CEPHEMA COMPOUNDS
KR950016760A (en) Hemorrhoids Treatment
KR910004191A (en) Renal disease treatment
KR910016660A (en) Di- and tetra-fluoro analogs of squalene as squalene epoxidase inhibitor
ATE73449T1 (en) 2-PIPERAZINYL-2-OXO-AETHYLENE-SUBSTITUTED FLAVONOID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
KR890014480A (en) 2-pyridylacetic acid derivative, preparation method thereof and pharmaceutical composition containing same
DE69018730D1 (en) Oxazolopyridine derivatives, processes for their preparation and pharmaceutical preparations containing them.
KR880000432A (en) 4 (3H) -oxo-5,6,7,8-tetrahydropyrido-2,3-d pyrimidine derivative
KR890016059A (en) Phosphonoalkylpurine Derivatives
KR940701251A (en) Cholesterol-lowering Tocopherol Homolog
OA08972A (en) New N- (vinblastinoyl-23) derivatives of 1-amino-methylphosphonic acid, their preparation processes and pharmaceutical compositions containing them
KR970064604A (en) Benzopyran derivatives and their use as therapeutic agents for heart disease
AP9801235A0 (en) Erythromycin derivatives.
EP0233745A3 (en) Chemical compounds
KR940000443A (en) Pyridyl-1,2,5-oxadiazolecarboxamide-2-oxide
KR910015301A (en) Treatment of Sleep Apnea

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
G170 Publication of correction
FPAY Annual fee payment

Payment date: 20111028

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20121114

Year of fee payment: 10

LAPS Lapse due to unpaid annual fee